RALEIGH, N.C., May 31, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care, today announced the presentation of data from four clinical studies at the National Lipid Association (NLA) Annual Scientific Sessions in Las Vegas, Nevada. The data demonstrate the value of measuring lipoprotein particles in a patient's blood sample as a tool for cardiovascular disease (CVD) management.
"Consistently, research is linking low-density lipoprotein particle number (LDL-P) and high-density lipoprotein particle number (HDL-P) to cardiovascular disease progression and events. The studies presented at NLA validate the importance of looking at lipoprotein particle numbers to individualize patient management and minimize cardiovascular risk," said Robert Honigberg, MD, Chief Medical Officer of LipoScience.
The data are to be presented today in the following posters during sessions starting at 12:30 p.m. PDT:
- Heterogeneity of LDL and HDL Particle Concentration in Subjects Meeting LDL-Cholesterol Goals
Presenters: James Underberg, MD and Gregory Pokrywka, MD
Abstract/Poster #: 101
- HDL Particle Number (HDL-P) Distribution in Patients with Angiographic Coronary Artery Disease on Lipid-Lowering Medication
Lead presenter: Hector Malave, MD
Abstract/Poster #: 102
- Lipoprotein Particle Number (LDL-P) Distribution in Polycystic Ovary Syndrome Patients
Lead presenter: Jason Reingold, MD
Abstract/Poster #: 105
- Discordance Between LDL Particle Number (LDL-P) and LDL-Cholesterol (LDL-C) Among Patients Treated at Two Medical Systems
Presenters: Kari Uusinarkaus, MD and Thomas White, MD
Abstract/Poster #: 107
In each of the studies, LDL-P and HDL-P were measured using LipoScience's proprietary NMR spectroscopy technology. The studies found that 55 to 75 percent of patients display discordance between low-density lipoprotein cholesterol (LDL-C) and LDL-P levels. Measuring lipoprotein particle number provides an opportunity to personalize patient management.
In one study, "Heterogeneity of LDL and HDL Particle Concentration in Subjects Meeting LDL-Cholesterol Goals," investigators studied the variations of LDL-P and HDL-P numbers to determine residual CVD risk in more than 6,500 patients who were at target LDL-C and high- density lipoprotein cholesterol (HDL-C) levels. The study found considerable discordance between cholesterol levels and particle numbers for both LDL and HDL, suggesting that quantifying lipoprotein particle concentrations may better identify residual risk for cardiovascular events than measuring cholesterol levels alone.
For more information on LipoScience and the studies being presented at NLA, please visit www.liposcience.com or the LipoScience booth at exhibit hall space #314.
About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.
LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.
SOURCE LipoScience, Inc.